HAAH is an excellent target for monoclonal antibody cancer therapeutics, and we have developed several high affinity antibodies against HAAH with good promise as cancer therapeutics," commented K.
This fact, coupled with the exclusivity of the surface expression of HAAH to cancer cells, suggests the potential clinical utility of PAN-622 for the specific delivery of cytotoxic agents to cancer cells.
HAAH over-expression has been detected in primary tumor tissue of all eighteen tumor types tested to date, including cancers of the pancreas, breast, ovary, liver, colon, prostate, lung, brain, and bile duct.
Recent findings in preclinical studies have indicated that over-expression of HAAH is sufficient to induce cellular transformation, to increase cell motility and invasiveness, and to establish tumor formation in animals.
In vitro, Panacea has shown that monoclonal antibodies against HAAH inhibit cell growth in a dose-dependent fashion, inhibit cell motility more than 6-fold and reduce invasion from 26% to 0.
HAAH was discovered by researchers at Brown University (Providence, RI) and the Rhode Island Hospital.
Panacea has identified HAAH
as a promising cancer biomarker target for diagnostic and therapeutic applications.
We are excited to be working with MedImmune to facilitate and expedite the development of compounds aimed at HAAH
," stated Hossein A.
The nanoparticle therapeutic cancer vaccine targeting HAAH
is clearly immunogenic in mice despite the high degree of homology to the human protein that makes the HAAH
resemble a self-antigen.
over-expression has been detected in greater than 95% of tumor specimens tested to date and has not been detected in adjacent normal tissue.
Inhibition of Tumor Growth in vivo by a Nanoparticle-Based Therapeutic Cancer Vaccine Targeting HAAH
Previously published studies have shown the over-expression of HAAH
in 100% of human cholangiocarcinomas, but not in regenerating bile duct cells.